(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (CST-2032 + nadolol)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(CST-2032 + nadolol) overview
A fixed-dose combination of CST-2032 and nadolol (CST-107) is under development for the treatment of mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease. The drug combination is administered orally. It acts by targeting beta-2 adrenoceptor.
CuraSen Therapeutics overview
CuraSen Therapeutics is developing drugs targeting a novel mechanism in the brain to restore function, improve symptoms and modify disease in a range of neurodegenerative diseases, including orphan disorders as well as Parkinson’s Disease and Alzheimer’s Disease.
For a complete picture of (CST-2032 + nadolol)’s drug-specific PTSR and LoA scores, buy the report here.